Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC   US23254L3069

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
0.6(c) 0.62(c) 0.61(c) 0.595(c) 0.58(c) Last
119 403 99 381 103 203 115 955 105 635 Volume
-2.25% +3.33% -1.61% -2.46% -2.52% Change
More quotes
Company
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company.It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail being... 
Sector
Biotechnology & Medical Research
Calendar
02/10 | 10:00amPresentation
More about the company
Surperformance© ratings of Cyclacel Pharmaceuticals I
Trading Rating : - Investor Rating :
More Ratings
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | CYCC | US23254L3069 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 1,28 M
EBIT 2014 -23,5 M
Net income 2014 -20,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 0,25 M
EBIT 2015 -26,8 M
Net income 2015 -25,2 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 10,4x
Capi. / Sales 2015 53,3x
Capitalization 13,3 M
More Financials
Latest news on CYCLACEL PHARMACEUTICALS I
01/06 Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conferen..
2014 CYCLACEL PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form..
2014 Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That ..
2014 CYCLACEL PHARMACEUTICALS : Other Events (form 8-K)
2014 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
2014 CYCLACEL PHARMACEUTICALS : Results of Operations and Financial Condition, Financ..
2014 CYCLACEL PHARMACEUTICALS : Reports Third Quarter 2014 Financial Results
2014 CYCLACEL PHARMACEUTICALS : to Release 2014 Third Quarter Financial Results
More news
Sector news Bio Therapeutic Drugs
01/30 PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF